Pfizer Inc. (NYSE:PFE) Shares Sold by Court Place Advisors LLC

Court Place Advisors LLC reduced its position in shares of Pfizer Inc. (NYSE:PFE) by 20.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 48,257 shares of the biopharmaceutical company’s stock after selling 12,185 shares during the period. Court Place Advisors LLC’s holdings in Pfizer were worth $1,389,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Worth Asset Management LLC acquired a new stake in shares of Pfizer during the first quarter valued at about $29,000. Briaud Financial Planning Inc acquired a new stake in Pfizer during the 3rd quarter valued at approximately $30,000. GoalVest Advisory LLC increased its holdings in Pfizer by 304.9% during the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 811 shares during the last quarter. Mizuho Securities Co. Ltd. acquired a new position in shares of Pfizer in the 3rd quarter valued at approximately $34,000. Finally, VisionPoint Advisory Group LLC boosted its stake in shares of Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 1,047 shares during the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Down 1.1 %

Shares of PFE stock traded down $0.29 on Wednesday, hitting $25.41. The company’s stock had a trading volume of 43,790,104 shares, compared to its average volume of 42,573,164. Pfizer Inc. has a fifty-two week low of $25.26 and a fifty-two week high of $41.33. The firm’s fifty day moving average price is $27.23 and its 200-day moving average price is $28.79. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. The stock has a market capitalization of $143.86 billion, a price-to-earnings ratio of 71.36, a P/E/G ratio of 1.18 and a beta of 0.61.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.29. The business had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. Pfizer’s quarterly revenue was down 41.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.14 EPS. Research analysts anticipate that Pfizer Inc. will post 2.22 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on PFE. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Monday. Guggenheim began coverage on Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price on the stock. Finally, TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price for the company. in a research report on Thursday, January 4th. Twelve equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $36.88.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.